Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders (2016 - 2026)
Quarterly results put Net Income towards Common Stockholders at -$115.3 million for Q1 2026, down 883.01% from a year ago — trailing twelve months through Mar 2026 was -$162.4 million (down 208.53% YoY), and the annual figure for FY2025 was -$53.2 million, changed 0.09%.
Armata Pharmaceuticals has reported Net Income towards Common Stockholders over the past 14 years, most recently at -$115.3 million for Q1 2026.
- Net Income towards Common Stockholders reached -$115.3 million in Q1 2026 per ARMP's latest filing, down from -$18.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$8.6 million in Q3 2022 and bottomed at -$115.3 million in Q1 2026.
- Median Net Income towards Common Stockholders over the past 5 years was -$11.7 million (2025), compared with a mean of -$18.8 million.
- The largest annual shift saw Net Income towards Common Stockholders surged 53.1% in 2025 before it plummeted 883.01% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at -$10.3 million in 2022, then dropped by 6.27% to -$11.0 million in 2023, then decreased by 26.07% to -$13.8 million in 2024, then tumbled by 35.01% to -$18.7 million in 2025, then plummeted by 518.25% to -$115.3 million in 2026.
- Business Quant data shows Net Income towards Common Stockholders for ARMP at -$115.3 million in Q1 2026, -$18.7 million in Q4 2025, and -$12.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Armata Pharmaceuticals | 301.92 Mn | 297.17 Mn | - | -115.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115.35 Mn |
| Dec 31, 2025 | -18.66 Mn |
| Sep 30, 2025 | -12.12 Mn |
| Jun 30, 2025 | -16.30 Mn |
| Mar 31, 2025 | -11.73 Mn |
| Dec 31, 2024 | -13.82 Mn |
| Sep 30, 2024 | -12.68 Mn |
| Jun 30, 2024 | -14.41 Mn |
| Mar 31, 2024 | -25.02 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -11.47 Mn |
| Jun 30, 2023 | -9.58 Mn |
| Mar 31, 2023 | -11.33 Mn |
| Dec 31, 2022 | -10.31 Mn |
| Sep 30, 2022 | -8.61 Mn |
| Jun 30, 2022 | -9.22 Mn |
| Mar 31, 2022 | -8.77 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | -6.15 Mn |
| Jun 30, 2021 | -6.19 Mn |
| Mar 31, 2021 | -5.50 Mn |
| Dec 31, 2020 | -6.55 Mn |
| Sep 30, 2020 | -5.77 Mn |
| Jun 30, 2020 | -4.71 Mn |
| Mar 31, 2020 | -5.08 Mn |
| Dec 31, 2019 | -4.59 Mn |
| Sep 30, 2019 | -6.96 Mn |
| Jun 30, 2019 | -4.20 Mn |
| Mar 31, 2019 | -3.62 Mn |
| Dec 31, 2018 | -8.91 Mn |
| Sep 30, 2018 | -1.63 Mn |
| Jun 30, 2018 | -3.05 Mn |
| Mar 31, 2018 | -3.13 Mn |
| Dec 31, 2017 | -2.33 Mn |
| Sep 30, 2017 | -779,000.00 |
| Jun 30, 2017 | -8.04 Mn |
| Mar 31, 2017 | -3.25 Mn |
| Dec 31, 2016 | -9.50 Mn |
| Sep 30, 2016 | -3.59 Mn |
| Jun 30, 2016 | -6.35 Mn |